MyoKardia, Inc. (NASDAQ:MYOK) insider Joseph Lambing sold 15,000 shares of MyoKardia stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now owns 119,718 shares in the company, valued at approximately $3,591,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Joseph Lambing also recently made the following trade(s):
- On Tuesday, August 15th, Joseph Lambing sold 5,000 shares of MyoKardia stock. The shares were sold at an average price of $40.00, for a total value of $200,000.00.
Shares of MyoKardia, Inc. (NASDAQ MYOK) traded down 7.184% on Friday, reaching $40.375. The company’s stock had a trading volume of 942,622 shares. MyoKardia, Inc. has a 1-year low of $10.55 and a 1-year high of $44.28. The stock has a 50-day moving average price of $21.23 and a 200-day moving average price of $15.10. The company’s market capitalization is $1.27 billion.
MyoKardia (NASDAQ:MYOK) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.04. The business had revenue of $5.60 million during the quarter, compared to analysts’ expectations of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. MyoKardia’s revenue for the quarter was up 60.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.37) EPS. On average, equities research analysts forecast that MyoKardia, Inc. will post ($1.64) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was first posted by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.baseball-news-blog.com/2017/08/20/insider-selling-myokardia-inc-myok-insider-sells-15000-shares-of-stock-updated.html.
Hedge funds have recently added to or reduced their stakes in the stock. Highbridge Capital Management LLC acquired a new stake in MyoKardia during the first quarter worth about $136,000. Trexquant Investment LP raised its stake in MyoKardia by 134.5% in the first quarter. Trexquant Investment LP now owns 37,987 shares of the biotechnology company’s stock worth $500,000 after buying an additional 21,787 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in MyoKardia during the second quarter worth about $629,000. Norges Bank acquired a new stake in MyoKardia during the fourth quarter worth about $869,000. Finally, Bank of New York Mellon Corp raised its stake in MyoKardia by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 56,605 shares of the biotechnology company’s stock worth $744,000 after buying an additional 8,469 shares during the last quarter. Institutional investors own 47.63% of the company’s stock.
Several equities analysts have issued reports on the company. ValuEngine upgraded MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. BMO Capital Markets restated a “buy” rating and set a $45.00 price target (up previously from $32.00) on shares of MyoKardia in a research note on Tuesday, August 8th. Wells Fargo & Company restated an “outperform” rating and set a $48.00 price target (up previously from $31.00) on shares of MyoKardia in a research note on Monday, August 7th. Cowen and Company boosted their price target on MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a research note on Monday, August 7th. Finally, TheStreet lowered MyoKardia from a “c-” rating to a “d+” rating in a research note on Friday, May 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $37.60.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.